Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Deisseroth

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Haematology and Blood Transfusion|January 1, 1990
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSFE H Estey, H M Kantarjian, M Beran, et al.
Blood|May 15, 1992
Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptorC F LeMaistre, C Meneghetti, M Rosenblum, et al.
The Journal of Clinical Investigation|November 1, 1990
A phosphatase activity present in peripheral blood myeloid cells of chronic myelogenous leukemia patients but not normal individuals alters nuclear protein binding to transcriptional enhancers of interferon-inducible genesD C Seong, S Sims, E Johnson, et al.
Blood|January 1, 1990
Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemiaR Mashal, M Shtalrid, M Talpaz, et al.
Blood|May 1, 1992
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSFE Estey, P F Thall, H Kantarjian, et al.
Lancet (London, England)|June 11, 1994
Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groupsP B McGlave, P De Fabritiis, A Deisseroth, et al.
International Journal of Cell Cloning|January 1, 1990
Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate the neutropenic trough of high-dose therapyG Spitzer, A Deisseroth, G Ventura, et al.
Blood|July 15, 1995
Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma?A H Sarris, T Esgleyes-Ribot, M Crow, et al.
American Journal of Human Genetics|September 23, 2023
Literature-based predictions of Mendelian disease therapiesCole A Deisseroth, Won-Seok Lee, Jiyoen Kim, et al.
Bone Marrow Transplantation|January 1, 1994
Biological characterization of stem cell present in mobilized peripheral blood of CML patientsA S Tsukamoto, C Reading, A Carella, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Haematology and Blood Transfusion|January 1, 1990
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSFE H Estey, H M Kantarjian, M Beran, et al.
Blood|May 15, 1992
Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptorC F LeMaistre, C Meneghetti, M Rosenblum, et al.
The Journal of Clinical Investigation|November 1, 1990
A phosphatase activity present in peripheral blood myeloid cells of chronic myelogenous leukemia patients but not normal individuals alters nuclear protein binding to transcriptional enhancers of interferon-inducible genesD C Seong, S Sims, E Johnson, et al.
Blood|January 1, 1990
Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemiaR Mashal, M Shtalrid, M Talpaz, et al.
Blood|May 1, 1992
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSFE Estey, P F Thall, H Kantarjian, et al.
Lancet (London, England)|June 11, 1994
Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groupsP B McGlave, P De Fabritiis, A Deisseroth, et al.
International Journal of Cell Cloning|January 1, 1990
Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate the neutropenic trough of high-dose therapyG Spitzer, A Deisseroth, G Ventura, et al.
Blood|July 15, 1995
Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma?A H Sarris, T Esgleyes-Ribot, M Crow, et al.
American Journal of Human Genetics|September 23, 2023
Literature-based predictions of Mendelian disease therapiesCole A Deisseroth, Won-Seok Lee, Jiyoen Kim, et al.
Bone Marrow Transplantation|January 1, 1994
Biological characterization of stem cell present in mobilized peripheral blood of CML patientsA S Tsukamoto, C Reading, A Carella, et al.
Pageof 11